Latest Breaking News On - European medicines agency regulations - Page 1 : comparemela.com
Global Diuretics (Diuril, Microzide, Indapamide) Market Report 2021: Long-term Forecast to 2025 & 2030
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Global Diuretics (Diuril, Microzide, Indapamide) Market Report 2021: Long-term Forecast to 2025 & 2030
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share:
New York, May 03, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Diuretics Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - https://www.reportlinker.com/p06067865/?utm source=GNW
91 billion in 2021 at a compound annual growth rate (CAGR) of 11%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.18 billion in 2025 at a CAGR of 6.7%.
The diuretic drugs market consists of sales of diuretic drugs and related services.Diuretic drugs help increase the flow of urine by reducing concentration of sodium and chloride in the body.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global diuretics drugs market is expected to decline from $0.9 billion in 2019 to $0.8 billion in 2020 at a compound annual growth rate (CAGR) of -17.9%.
Diuretics Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global diuretics drugs market as it emerges from the COVID-19 shut down.
The decline is mainly due to the disruption caused by the lockdown measure across various countries to contain COVID-19 spread. Currently there is less demand for genito-urinary drugs mainly as people are staying at home and are less likely to get exposed to factors that might cause genito-urinary infections, or other hormonal diseases caused by lifestyle changes or eating habits. The market is then expected to recover and grow at a CAGR of 5.8% from 2021 and reach $1.1 billion in 2023.